Evidence map›Paper›PMID 40721644›Full record

ArticleScientific reports2025

Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer.

Wenying Jiang, Maonan Wang, Qingning Chen, Xiaoqian Yu, Guoqian Liu, Xiaoyun He, Cheng Mei, Chunlin Ou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenying Jiang *Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Maonan Wang *Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, Changsha, 410000, Hunan, China.
Qingning ChenDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xiaoqian YuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Guoqian LiuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xiaoyun HeDepartments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Cheng MeiDepartment of Blood Transfusion, Xiangya Hospital, Clinical Transfusion Research Center, Central South University, Changsha, 410008, Hunan, China. meicheng@csu.edu.cn.
Chunlin OuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. ouchunlin@csu.edu.cn.

Funding

Central South University Innovation-Driven Research Programme 2023CXQD075National Natural Science Foundation of China 82303841Natural Science Foundation of Hunan Province 2023JJ40800Natural Science Foundation of Hunan Province 2023JJ40975Youth Science Foundation B of Hunan Province 2025JJ40071
6 · The paper itself

Abstract

The incidence of breast cancer continues to increase annually, posing a significant challenge for countries worldwide in terms of its prevention and treatment. Therefore, identifying novel therapeutic targets for breast cancer is urgently needed. The peroxiredoxin (PRDX) family is regarded as a good diagnostic marker for various tumors. However, the expression and prognostic significance of PRDX family members in breast cancer remain unclear and require systematic investigation. By using bioinformatic tools such as UALCAN, TIMER2.0, Human Protein Atlas Project (HPA), Gene Set Cancer Analysis (GSCA), and the cBioportal database, we systematically analyzed the expression pattern, prognostic value, methylation status and immune infiltrating association of PRDX gene family members in breast cancer. Through comprehensive analysis, we found that PRDX4 has good prognostic value and is closely related to immune infiltration, and further exploration of its oncogenic function in breast cancer is warranted. Subsequently, we performed a series of cellular assays to explore the potential role of PRDX4 in the progression of breast cancer. We demonstrated that PRDX4 promoted the proliferation, invasion, metastasis, and inhibited the apoptosis of breast cancer cells. In addition, PRDX4 expression was associated with the half maximal inhibitory concentration (IC

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmPeroxiredoxinsApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorPeroxiredoxinsPRDX4 protein, humanBreast cancerDrug resistanceImmune infiltrationPRDX4PrognosisTherapeutic target

Identifiers

PMID40721644
PMCPMC12304276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.